For the past few years, the centre of gravity in competitive fitness has shifted. While the CrossFit Games remains the pinnacle of elite performance for many, the rise of Hyrox has shown just how ...

While previous embedding models were largely restricted to text, this new model natively integrates text, images, video, audio, and documents into a single numerical space — reducing latency by as muc ...

Frequency Electronics, Inc. (NASDAQ:FEIM) Q3 2026 Earnings Call Transcript March 11, 2026 Frequency Electronics, Inc. misses on earnings expectations. Reported EPS is $0.1606 EPS, expectations were $0 ...

biote Corp. (NASDAQ:BTMD) Q4 2025 Earnings Call Transcript March 11, 2026 biote Corp. beats earnings expectations. Reported EPS is $0.06339, expectations were $0.04. Operator: Good day, and welcome to ...

Corp. undertakes no obligation to update them in the future. Therefore, statements should not be relied upon as representing the company's views as of any subsequent date. For discussion of risks and ...

Over the past decade, however, a wave of technological advances has begun to expand the druggable proteome. These include covalent inhibitors (such as sotorasib), chemical proteomics, and AI-enabled ...

Greetings, and welcome to the Frequency Electronics Third Quarter Fiscal 2026 Earnings Release Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. Any statements ...

As many as half of all nursing home patients may benefit from respiratory therapy, given rising complexity and common conditions such as COPD, congestive heart failure and other chronic breathing and ...

“Spot On”: An art exhibition, titled “Spot On, aka, See Spot Run,” is currently on display at 68 Prince Street Gallery, 68 Prince St., Kingston. The exhibition features art by Sharon Butler. Jason ...

West Pharmaceutical Services, Inc. ( WST) Barclays 28th Annual Global Healthcare Conference March 10, 2026 9:00 AM EDT ...

A Nasdaq-listed biotechnology company repositioned as a global platform for acquiring and advancing clinical-stage assets. NovaBridge Biosciences is built around two principal programs, givastomig in ...

Reported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) ...